Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years or older in generally good health who are scheduled to have a total hysterectomy and who are willing to limit alcohol consumption~Exclusion Criteria:~* Patient is allergic to the study drug, other cyclooxygenase-2 (COX-2) inhibitors/nonsteroidal anti-inflammatory drugs (NSAIDS), ibuprofen, morphine, or oxycodone or has hypersensitivity to aspirin or other NSAIDS~* Patient has uncontrolled high blood pressure~* Patient has a history of drug and/or alcohol abuse within the last 5 years~* Patient has taken part in another investigational study within 4 weeks of the start of study~* Patient is breast-feeding~* Patient has an active ulcer or inflammatory bowel disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib 120 mg (Type: EXPERIMENTAL): etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
- Etoricoxib 90 mg (Type: EXPERIMENTAL): etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo- 3 tablets once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).